Altimmune ALT 深 沪
等待开盘 03-26 09:30:00 美东时间
3.34
+0.100
+3.09%
华盛通- 最 高3.385
- 今 开3.30
- 成交量 102.65万股
- 最 低 3.30
- 昨 收 3.24
- 总市值 4.34亿
- 52周最高 7.73
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.90
- 委 比 -21.06%
- 总股本 1.30亿
- 历史最高 237.30
- 量 比 0.27
- 振 幅 2.62%
- 历史最低 1.51
- 每 手 1
- 风险率 0.89%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Anti-Aging Protein Research Takes a Step Forward with Cell Cloning
Issued on behalf of Avaí Bio, Inc. VANCOUVER, BC, March 24, 2026 /PRNewswire/ -- Equity-Insider.com — A protein called α-Klotho circulating in the bloodstream protects the brain, heart, kidn...
03-24 23:05
美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
HC Wainwright & Co. Maintains Buy on Altimmune, Raises Price Target to $25
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy and raises the price target from $12 to $25.
03-17 00:17
Altimmune, Coherent, Globalstar, Bed Bath & Beyond, Linde Insider Shocks
Insiders have been trading these 5 stocks: (($ALT)), (($COHR)), (($GSAT)), (($B...
03-14 21:01
美股大行评级 | 潜在涨幅183%！迈威尔科技获10家机构上调目标价最高至164美元；伯灵顿百货、好市多、Ciena、Samsara等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持BridgeBio Oncology"买入"评级，目标价从27美元升至29美元；韦德布什：维持WAVE Life Sciences"跑赢大市"评级，目标价从33美元升至35美元
03-09 11:47
B. Riley Securities Maintains Buy on Altimmune, Lowers Price Target to $13
B. Riley Securities analyst William Woods maintains Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $18 to $13.
03-07 00:21
Altimmune Inc. Announces 2026 Annual Stockholders Meeting
Altimmune Inc. Announces 2026 Annual Stockholders Meeting Altimmune, Inc. will hold its 2026 annual meeting virtually on April 16, 2026. Stockholders will vote on the election of nine directors and the ratification of Ernst & Young LLP as independent registered public accounting firm for 2026. The m
03-06 21:02
Altimmune shares are trading lower. The company reported Q4 financial results.
Altimmune shares are trading lower. The company reported Q4 financial results.
03-06 01:09
Altimmune: Q4 Earnings Insights
Altimmune (NASDAQ:ALT) released its Q4 earnings on Thursday, March 5, 2026 at 0...
03-05 20:28
Altimmune Q4 EPS $(0.27) Up From $(0.33) YoY, Sales $26.000K Up From $5.000K YoY
Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.27) per share. This is a 18.18 percent increase over losses of $(0.33) per share from the same period last year. The company reported $26.000 thousand in sales
03-05 20:27
